Drugs

Chemotherapy with adjuvant nivolumab versus placebo for GEJ cancer

Photo taken from primewomen.com

Jun 29, 2024, 13:50

Chemotherapy with adjuvant nivolumab versus placebo for GEJ cancer

Syed A. Ahmad, Chief of Surgical Oncology at The University of Cincinnati, made the following post on X:

“Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5)⁦ .”

Additional information.
Source: Syed A. Ahmad/X

cancer chemotherapy gastric cancer gastro-oesophageal junction cancer Hyun Cheol Chung Jen-Shi Chen Jiafu Ji Jong Gwang Kim Keun Won Ryu Li-Tzong Chen Li-Yuan Bai lymph-node dissection Masanori Terashima Min-Hee Ryu Mitsuru Sasako Narikazu Boku nivolumab Norimasa Fukushima OncoDaily Oncology Shinichi Sakuramoto Shunsuke Hagihara Sun Young Rha Syed A. Ahmad Ta-Sen Yeh Tae Yong Kim Takanobu Yamada Takashi Nakada Takeshi Omori The University of Cincinnati Yasunori Nishida Yoon-Koo Kang Yoshinori Hirashima Young Woo Kim

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer